The NHLBI Grants NuvOx Pharma a 300K Grant to Study the Effects of Their Oxygen Therapeutic on Myocardial Infarction in a Pig Model
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $317,743 for a study in pigs for NuvOx Pharma's drug, NVX-308, in heart attack.
Tucson, AZ, April 14, 2017 --(PR.com)-- Evan Unger, MD, President and CEO of NuvOx Pharma, announced that NuvOx Pharma has been awarded a grant from the National Heart, Lung, and Blood Institute (NHLBI) entitled “Dodecafluoropentane Prevents Ischemia Reperfusion Injury in Contemporary Acute Myocardial Infarction Management,” for a total of $317,743. This grant will be used to support research to study NVX-308 as a cardioprotectant to reduce damage to the heart following myocardial infarction.
Dr. Thomas Porter, MD, Distinguished Chair of Cardiology in the Department of Internal Medicine at the University of Nebraska, said, “NVX-308 has shown promise in significantly reducing heart damage following myocardial infarction in small animal studies. In the upcoming studies funded by the grant, we will test NVX-308 in a pig model with coronary artery disease to determine if NVX-308 significantly reduces heart damage in this highly relevant animal model. If NVX-308 shows significant promise, this data will be used to support an Investigational New Drug application to study NVX-308 in patients with heart attack.”
Heart attack affects approximately 735,000 people each year in the United States and is the number one cause of death.(1) New treatments, such as NVX-308, are needed to potentially reduce heart damage to not only improve survival, but also to improve heart function following myocardial infarction. Additionally, about 5.7 million Americans are currently living with congestive heart failure.1 If we could improve or reduce heart damage in this patient population, then patient quality of life would greatly improve, and patient-related health expenses would decrease.
NuvOx Pharma is a clinical stage pharmaceutical company that is developing a platform of oxygen therapeutics. In addition to the above pre-clinical stage indication, the company also has completed a Phase Ib/II trial in brain cancer, has a product in a Phase Ib/II clinical trial in acute ischemic stroke, and has an IND allowed for a Phase Ib clinical trial for sickle cell crisis. For further information, please see www.nuvoxpharma.com or contact John McGonigle at jmcgonigle@nuvoxpharma.com.
Disclaimer: Certain statements in this release may constitute “forward-looking statements.” Actual events or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.
(1) Mozzafarian D, Benjamin EJ, Go AS, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2016 update: a report from the American Heart Association. Circulation. 2016;133:e38-e360.
Dr. Thomas Porter, MD, Distinguished Chair of Cardiology in the Department of Internal Medicine at the University of Nebraska, said, “NVX-308 has shown promise in significantly reducing heart damage following myocardial infarction in small animal studies. In the upcoming studies funded by the grant, we will test NVX-308 in a pig model with coronary artery disease to determine if NVX-308 significantly reduces heart damage in this highly relevant animal model. If NVX-308 shows significant promise, this data will be used to support an Investigational New Drug application to study NVX-308 in patients with heart attack.”
Heart attack affects approximately 735,000 people each year in the United States and is the number one cause of death.(1) New treatments, such as NVX-308, are needed to potentially reduce heart damage to not only improve survival, but also to improve heart function following myocardial infarction. Additionally, about 5.7 million Americans are currently living with congestive heart failure.1 If we could improve or reduce heart damage in this patient population, then patient quality of life would greatly improve, and patient-related health expenses would decrease.
NuvOx Pharma is a clinical stage pharmaceutical company that is developing a platform of oxygen therapeutics. In addition to the above pre-clinical stage indication, the company also has completed a Phase Ib/II trial in brain cancer, has a product in a Phase Ib/II clinical trial in acute ischemic stroke, and has an IND allowed for a Phase Ib clinical trial for sickle cell crisis. For further information, please see www.nuvoxpharma.com or contact John McGonigle at jmcgonigle@nuvoxpharma.com.
Disclaimer: Certain statements in this release may constitute “forward-looking statements.” Actual events or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.
(1) Mozzafarian D, Benjamin EJ, Go AS, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2016 update: a report from the American Heart Association. Circulation. 2016;133:e38-e360.
Contact
NuvOx Pharma
John McGonigle
(520) 624-6688
www.nuvoxpharma.com
John McGonigle
(520) 624-6688
www.nuvoxpharma.com
Contact
Categories